NCT02989636View on ClinicalTrials.gov

Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

March 10, 2017

Primary Completion Date

April 24, 2024

Study Completion Date

November 30, 2026

Conditions
Chordoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nivolumab

Given IV

RADIATION

Stereotactic Radiosurgery

Undergo SRS

Trial Locations (2)

10065

Memorial Sloan-Kettering Cancer Center, New York

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Chordoma Foundation

OTHER

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT02989636 - Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma | Biotech Hunter | Biotech Hunter